Ruiz de Porras, V.; Bakht, M.K.; Fernandez-SaorÃn, M.; Alcon, C.; Palomero, L.; Francisco-Rodon, J.; Figols, M.; Montero, J.; Conteduca, V.; Beltran, H.;
et al. YM155 Inhibition of Survivin Enhances Carboplatin Efficacy in Metastatic Castration-Resistant Prostate Cancer. Pharmaceuticals 2025, 18, 1752.
https://doi.org/10.3390/ph18111752
AMA Style
Ruiz de Porras V, Bakht MK, Fernandez-SaorÃn M, Alcon C, Palomero L, Francisco-Rodon J, Figols M, Montero J, Conteduca V, Beltran H,
et al. YM155 Inhibition of Survivin Enhances Carboplatin Efficacy in Metastatic Castration-Resistant Prostate Cancer. Pharmaceuticals. 2025; 18(11):1752.
https://doi.org/10.3390/ph18111752
Chicago/Turabian Style
Ruiz de Porras, Vicenç, Martin K. Bakht, Maria Fernandez-SaorÃn, Clara Alcon, Luis Palomero, Júlia Francisco-Rodon, Mariona Figols, Joan Montero, Vincenza Conteduca, Himisha Beltran,
and et al. 2025. "YM155 Inhibition of Survivin Enhances Carboplatin Efficacy in Metastatic Castration-Resistant Prostate Cancer" Pharmaceuticals 18, no. 11: 1752.
https://doi.org/10.3390/ph18111752
APA Style
Ruiz de Porras, V., Bakht, M. K., Fernandez-SaorÃn, M., Alcon, C., Palomero, L., Francisco-Rodon, J., Figols, M., Montero, J., Conteduca, V., Beltran, H., & Font, A.
(2025). YM155 Inhibition of Survivin Enhances Carboplatin Efficacy in Metastatic Castration-Resistant Prostate Cancer. Pharmaceuticals, 18(11), 1752.
https://doi.org/10.3390/ph18111752
